Monte Rosa Therapeutics, Inc.
- Open
- 22.54
- Day high
- 24.71
- Day low
- 22.11
- Prev close
- 23.16
- Volume
- 1.2M
- Mkt cap
- $2.1B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.0
- P/S
- 48.3
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$2.4M over the last 3 months (0 open-market buys, 19 sales)
- 🏛Institutions accumulating (13F)
Monte Rosa Therapeutics, Inc. (GLUE) is a Healthcare company listed on NASDAQ. The stock is up 313% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 19 sales (SEC Form 4).
Monte Rosa Therapeutics, Inc. (GLUE) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GLUE earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.28 | $-0.45 | -60.7% | $4M | -61.7% |
| Mar 17, 2026 | $-0.35 | $-0.54 | -53.6% | $3M | -82.0% |
| Nov 6, 2025 | $-0.39 | $-0.33 | +15.4% | $13M | -17.7% |
| Aug 7, 2025 | $-0.31 | $-0.15 | +51.6% | $23M | +198.4% |
| May 8, 2025 | $-0.24 | $0.57 | +337.5% | $85M | +526.0% |
| Mar 20, 2025 | $-0.37 | $0.23 | +162.2% | $61M | +30.0% |
| Nov 7, 2024 | $-0.45 | $-0.29 | +35.6% | $9M | +249.3% |
| Aug 8, 2024 | $-0.50 | $-0.43 | +14.0% | $5M | +248.1% |
| May 9, 2024 | $-0.56 | $-0.53 | +5.4% | $1M | -24.0% |
| Mar 14, 2024 | $-0.57 | $-0.58 | -1.8% | $9M | +148.1% |
| Nov 9, 2023 | $-0.75 | $-0.70 | +6.7% | — | — |
| Aug 10, 2023 | $-0.72 | $-0.71 | +1.4% | — | — |
GLUE insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 16, 2026 | Champoux Jenniferofficer: Chief Operating Officer | Sell | 4,351 | $23.38 |
| Jul 16, 2026 | Champoux Jenniferofficer: Chief Operating Officer | Option | 4,351 | $3.98 |
| Jul 7, 2026 | Townson Sharonofficer: Chief Scientific Officer | Option | 6,000 | $6.14 |
| Jul 7, 2026 | Townson Sharonofficer: Chief Scientific Officer | Sell | 5,600 | $23.25 |
| Jul 7, 2026 | Townson Sharonofficer: Chief Scientific Officer | Sell | 400 | $24.13 |
| Jul 1, 2026 | Janku Filipofficer: Chief Medical Officer | Sell | 5,407 | $24.50 |
| Jul 1, 2026 | Janku Filipofficer: Chief Medical Officer | Option | 5,407 | $13.41 |
| Jun 30, 2026 | Janku Filipofficer: Chief Medical Officer | Option | 6,000 | $7.56 |
| Jun 30, 2026 | Manning Anthony M.director | Sell | 10,000 | $23.11 |
| Jun 30, 2026 | Manning Anthony M.director | Option | 10,000 | $4.16 |
| Jun 30, 2026 | Janku Filipofficer: Chief Medical Officer | Sell | 6,000 | $22.95 |
| Jun 25, 2026 | Champoux Jenniferofficer: Chief Operating Officer | Sell | 2,175 | $20.00 |
| Jun 25, 2026 | Townson Sharonofficer: Chief Scientific Officer | Option | 3,000 | $6.14 |
| Jun 25, 2026 | Townson Sharonofficer: Chief Scientific Officer | Sell | 3,000 | $20.00 |
| Jun 25, 2026 | Janku Filipofficer: Chief Medical Officer | Sell | 11,845 | $20.22 |
Source: GLUE SEC Form 4 filings, latest Jul 16, 2026. For informational purposes only — not investment advice.
See the full GLUE insider & 13F page →Monte Rosa Therapeutics, Inc. company profile
Overview
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Boston, Massachusetts. The company went public in June 2021 and specializes in developing innovative small molecule precision medicines that harness the body's natural protein degradation systems to treat cancer and immune-mediated diseases. Monte Rosa has emerged as a pioneer in the molecular glue degrader space, with multiple programs advancing through clinical development across oncology and immunology therapeutic areas.
Business
Monte Rosa Therapeutics operates in the biotechnology sector, specifically focusing on targeted protein degradation using molecular glue degraders. This represents a novel approach to drug discovery that goes beyond traditional methods of blocking protein function. The company's core technology platform centers on molecular glue degraders - small molecules that work by bringing together target proteins with the cell's natural protein disposal system (called the ubiquitin-proteasome system). Think of it like introducing a "matchmaker" molecule that connects unwanted disease-causing proteins to the cell's recycling machinery, leading to their selective destruction rather than just blocking their function. Monte Rosa's pipeline is organized into two main therapeutic areas: Immunology & Inflammation Program (Primary Focus): This segment includes MRT-6160, which targets VAV1 protein degradation for treating autoimmune diseases, and the NEK7 program targeting inflammatory pathways. The VAV1 program has shown particularly promising results with 80-99% cytokine inhibition in early trials and has attracted a strategic collaboration with pharmaceutical giant Novartis. This appears to represent the majority of the company's current focus and potential near-term value. Oncology Program: This includes MRT-2359 targeting GSPT1 for Myc-driven cancers (currently focused on castration-resistant prostate cancer), and cell cycle programs targeting CDK2 and Cyclin E1 for various solid tumors including breast, ovarian, and uterine cancers. While showing clinical activity, this segment appears secondary to the immunology focus based on recent strategic decisions. The company's approach is fundamentally different from traditional pharmaceuticals because instead of blocking proteins (like putting a lock on a door), molecular glue degraders eliminate the proteins entirely (like removing the door altogether), potentially offering more durable therapeutic effects.
Revenue model
Monte Rosa generates revenue primarily through strategic partnerships and collaborations rather than product sales, as it remains in the clinical development stage with no approved products. The company's business model follows the typical biotech pattern of partnership-driven revenue during development phases. The primary revenue streams include upfront payments, milestone payments, and research funding from pharmaceutical partners. The most significant partnership is with Novartis for the VAV1 program, which has provided substantial funding and validation. Revenue has been highly variable, ranging from minimal amounts in early quarters to $85 million in Q1 2025, reflecting the lumpy nature of milestone-based payments. Key factors that influence the company's financial performance and margins include: Positive factors: Successful clinical trial results drive milestone payments and can attract new partnerships. The molecular glue degrader platform's novelty and broad applicability across multiple disease areas creates opportunities for multiple partnerships. Strong intellectual property position in the emerging protein degradation field provides competitive advantages. The Novartis collaboration validates the platform and provides both funding and expertise. Negative factors: Clinical trial failures can eliminate revenue streams and require costly program pivots, as seen with discontinuation of certain MRT-2359 expansion cohorts. The high cost of clinical development, particularly for multiple simultaneous programs, creates significant cash burn. Regulatory delays can postpone milestone payments and extend development timelines. Competition in the protein degradation space is intensifying as larger pharmaceutical companies develop internal capabilities. The company's customers are primarily large pharmaceutical companies seeking innovative therapeutic approaches, with Novartis being the key strategic partner currently providing the most significant revenue contribution.
Competitive moat
Monte Rosa's competitive moat is moderately strong but not insurmountable, built primarily on its early-mover advantage and specialized expertise in molecular glue degraders, a relatively new therapeutic modality. The company's strongest moat elements include its proprietary QuEEN platform (Quantitative and Engineered Elimination of Neosubstrates) for discovering molecular glue degraders, which represents years of accumulated knowledge and proprietary screening capabilities. The platform enables systematic identification of molecular glues that can degrade previously "undruggable" proteins, providing access to novel therapeutic targets. Additionally, Monte Rosa has built substantial intellectual property around specific molecular glue degraders and has established important partnerships, particularly with Novartis, that provide both validation and resources. However, the moat faces significant challenges. The protein degradation field is rapidly evolving with major pharmaceutical companies like Roche, Bristol Myers Squibb, and others developing competing approaches including PROTACs (Proteolysis Targeting Chimeras) and their own molecular glue programs. The scientific principles underlying protein degradation are becoming more widely understood, reducing the knowledge barrier for competitors. The company's moat is further limited by the inherent risks of clinical-stage biotechnology - even with superior technology, clinical failures can eliminate competitive advantages overnight. The molecular glue degrader space, while promising, remains unproven at scale with no approved products yet in the market. Monte Rosa's moat is best characterized as a temporary technological lead that must be continuously reinforced through successful clinical execution and continued innovation. The partnership with Novartis helps strengthen this position, but the ultimate sustainability of the moat will depend on achieving clinical and commercial success before competitors catch up.
Risks & safety
Monte Rosa presents a moderate margin of safety typical of clinical-stage biotechnology companies, with strong liquidity but inherent execution risks. • Liquidity position: Strong cash position of $78.5 million as of Q1 2025, with management guidance for cash runway extending into 2028 • Debt levels: Low debt-to-equity ratio of 0.15, indicating minimal financial leverage and solvency risk • Current ratio: Excellent liquidity with current ratio of 5.61, providing substantial cushion for operational needs • Cash burn: Free cash flow of -$47 million in Q1 2025, though this varies significantly due to milestone-based revenue recognition • Valuation metrics: Trading at P/E ratio of 2.03 and EV/EBITDA of 1.87 based on recent profitable quarters, though these metrics are distorted by partnership milestone payments rather than sustainable earnings • Graham metrics: Graham net-net value of 2.55 suggests the stock trades below conservative asset-based valuations • Other considerations: Clinical-stage biotech carries binary risk from trial outcomes, but Novartis partnership provides validation and reduces execution risk somewhat
Recent development
Over the past few years, Monte Rosa has executed a significant strategic pivot toward immunology and inflammation while maintaining a focused oncology portfolio. The most transformative development has been the Novartis collaboration around the VAV1 program (MRT-6160), which has provided both substantial funding and strategic validation of the molecular glue degrader platform. In the immunology space, MRT-6160 has shown remarkable clinical progress with 80-99% cytokine inhibition in Phase 1 trials, demonstrating the potential for broad applications across immune-mediated diseases. The company has advanced the NEK7 program targeting inflammatory pathways, with IND submission planned for the first half of 2025, expanding the immunology pipeline beyond VAV1. The oncology strategy has become more focused and selective. While MRT-2359 (GSPT1 degrader) has shown encouraging results in castration-resistant prostate cancer with confirmed partial responses, the company made the strategic decision to discontinue expansion cohorts in lung cancer and high-grade neuroendocrine tumors to concentrate resources on the most promising indications. The cell cycle programs targeting CDK2 and Cyclin E1 have advanced with strong preclinical results, though IND submission has been pushed to 2026. A key strategic development has been the evolution from a broad-based oncology focus to a more balanced approach emphasizing immunology, reflecting both the clinical promise of the VAV1 program and the substantial market opportunity in autoimmune diseases. This pivot has been supported by the Novartis partnership, which provides both financial resources and expertise in immunology drug development. The company has also strengthened its QuEEN platform capabilities, enabling more systematic discovery of molecular glue degraders across multiple target proteins, positioning Monte Rosa as a leader in this emerging therapeutic modality.
GLUE company profile · for informational purposes only — not investment advice.
Track GLUE with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free